Congress Materials

Medical Information
Afrique
 

This medical information website is intended only for healthcare professionals in Africa. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
I am not a Healthcare ProfessionalNo, go back to the patient portal
SelectI am not a Healthcare ProfessionalNo, go back to the patient portal
Where do you work / live?
SubmitSubmit
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Oral Presentation
Grivas P, Bellmunt J, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Blake-Haskins JA, Laliberte RJ, Wang J, Costa N, Powles T May 13, 2022 AUA 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up Results From the JAVELIN Bladder 100 Trial

View Presentation View Abstract Plain Language Summary
Poster
Mehlhaff B, Shore ND, George DJ, Cookson MS, Saltzstein DR, Tutrone R, Bailen JL, Brown B, Langenberg AGM, Fallick M, Lu S, Hanson S, Tombal B, Saad F May 14, 2022 AUA 2022 Prostate Cancer

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis From the Randomized Phase 3 HERO Study

View Presentation View Abstract Plain Language Summary
Poster
Shore ND, Iguchi T, Villers A, Azad AA, Szmulewitz RZ, Holzbeierlein J, Alcaraz A, Alekseev B, Gomez-Veiga F, Rosbrook B, Lee H-J, Haas GP, Armstrong AJ, Stenzl A May 14, 2022 AUA 2022 Prostate Cancer

Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated With Enzalutamide or Placebo Plus Androgen Deprivation Therapy who had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial

View Presentation View Abstract Plain Language Summary
Poster
Lowentritt B, Fallick M, Dufour R, Pruett J, Jiang T, Nwokeji E, Nagao M May 15, 2022 AUA 2022 Prostate Cancer

Evaluating Cardiovascular Risk in Men Starting Androgen Deprivation Therapy for Prostate Cancer

View Presentation View Abstract Plain Language Summary
Oral Presentation
Bailen JL, Saad F, George DJ, Mehlhaff B, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Langenberg AGM, Lu S, Lee J, Hanson S,  Tombal B, Shore ND May 15, 2022 AUA 2022 Prostate Cancer

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies

View Presentation View Abstract Plain Language Summary